» Articles » PMID: 35334877

Vitamin D and Parkinson's Disease

Overview
Journal Nutrients
Date 2022 Mar 26
PMID 35334877
Authors
Affiliations
Soon will be listed here.
Abstract

Vitamin D is a fat-soluble secosteroid, traditionally considered a key regulator of bone metabolism, calcium and phosphorous homeostasis. Its action is made possible through the binding to the vitamin D receptor (VDR), after which it directly and indirectly modulates the expression of thousands of genes. Vitamin D is important for brain development, mature brain activity and associated with many neurological diseases, including Parkinson's disease (PD). High frequency of vitamin D deficiency in patients with Parkinson's disease compared to control population was noted nearly twenty years ago. This finding is of interest given vitamin D's neuroprotective effect, exerted by the action of neurotrophic factors, regulation of nerve growth or through protection against cytotoxicity. Vitamin D deficiency seems to be related to disease severity and disease progression, evaluated by Unified Parkinson's Disease Rating Scale (UPDRS) and Hoehn and Yahr (H&Y) scale, but not with age of PD onset and duration of disease. Additionally, fall risk has been associated with lower vitamin D levels in PD. However, while the association between vitamin D and motor-symptoms seems to be possible, results of studies investigating the association with non-motor symptoms are conflicting. In addition, very little evidence exists regarding the possibility to use vitamin D supplementation to reduce clinical manifestations and disability in patients with PD. However, considering the positive balance between potential benefits against its limited risks, vitamin D supplementation for PD patients will probably be considered in the near future, if further confirmed in clinical studies.

Citing Articles

The Advances in Antipsychotics-Induced Dyskinesia Rodent Models: Benefits of Antioxidant Supplementation.

Velickovic U, Selakovic D, Jovicic N, Mitrovic M, Janjic V, Rosic S Biomedicines. 2025; 13(2).

PMID: 40002925 PMC: 11853207. DOI: 10.3390/biomedicines13020512.


Association of 25-hydroxyvitamin D with Parkinson's disease based on the results from the NHANES 2007 to 2018 and Mendelian randomization analysis.

Xu Y, Peng J, Zhou X, Huang Y, Zhong G, Xia Z Sci Rep. 2025; 15(1):5514.

PMID: 39953081 PMC: 11828982. DOI: 10.1038/s41598-025-87120-6.


Vitamins in the Prevention and Support Therapy of Neurodegenerative Diseases.

Orywal K, Socha K, Iwaniuk P, Kaczynski P, Farhan J, Zon W Int J Mol Sci. 2025; 26(3).

PMID: 39941101 PMC: 11818229. DOI: 10.3390/ijms26031333.


Association between serum vitamin D and severe headache or migraine: A population-based analysis.

Hao S, Qian R, Chen Y, Liu J, Xu X, Guan Y PLoS One. 2025; 20(1):e0313082.

PMID: 39752405 PMC: 11698344. DOI: 10.1371/journal.pone.0313082.


Unraveling the Bone-Brain Axis: A New Frontier in Parkinson's Disease Research.

Liu T, Wu H, Li J, Zhu C, Wei J Int J Mol Sci. 2024; 25(23).

PMID: 39684552 PMC: 11641043. DOI: 10.3390/ijms252312842.


References
1.
Lang F, Ma K, Leibrock C . 1,25(OH)D in Brain Function and Neuropsychiatric Disease. Neurosignals. 2019; 27(1):40-49. DOI: 10.33594/000000182. View

2.
Wang L, Evatt M, Maldonado L, Perry W, Ritchie J, Beecham G . Vitamin D from different sources is inversely associated with Parkinson disease. Mov Disord. 2014; 30(4):560-6. PMC: 4390412. DOI: 10.1002/mds.26117. View

3.
Cass W, Peters L, Fletcher A, Yurek D . Calcitriol promotes augmented dopamine release in the lesioned striatum of 6-hydroxydopamine treated rats. Neurochem Res. 2014; 39(8):1467-76. PMC: 4125437. DOI: 10.1007/s11064-014-1331-1. View

4.
Zhu D, Liu G, Lv Z, Wen S, Bi S, Wang W . Inverse associations of outdoor activity and vitamin D intake with the risk of Parkinson's disease. J Zhejiang Univ Sci B. 2014; 15(10):923-7. PMC: 4201321. DOI: 10.1631/jzus.B1400005. View

5.
Smith M, Fletcher-Turner A, Yurek D, Cass W . Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine. Neurochem Res. 2006; 31(4):533-9. DOI: 10.1007/s11064-006-9048-4. View